CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Inclusion Criteria: Previously untreated, histologically proven T-cell Lymphoma (any of the following): * Peripheral T-cell lymphoma Not Otherwise Specified (PTCL NOS) * Systemic Anaplastic large cell lymphoma (ALCL) ALK negative cases only * Angioimmunoblastic T-cell lymphoma * Hepatosplenic gamma/ delta T-cell lymphoma * Enteropathy-associated T-cell lymphoma (EATL) * Bulky stage I not being considered for reduced chemotherapy plus involved field radiotherapy or stage II, III or IV. * Patient is male or female, and ≥18 years of age on the day of signing informed consent. * WHO performance status 0, 1 or 2. * Cross sectional imaging from a baseline contrast enhanced CT should show at least one measurable disease site that is at least 2 cm in longest diameter and measurable in two perpendicular dimensions with or without corresponding Fluorodeoxyglucose(FDG) avid lesions. * Adequate cardiac function; formal assessment of left ventricular ejection fraction is only required if clinically indicated (a baseline echocardiogram should be done for patients with either hypertension, age \> 60 years or history of cardiac disease) * Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.0x109/l; white blood cell count ≥ 3x109/l; platelets ≥ 100x109/l; haemoglobin (Hb) ≥ 9g/dl (can be post-transfusion), unless deemed disease related * Adequate renal function: calculated creatinine clearance ≥50ml/minute. * Adequate liver function: serum bilirubin ≤1.5x Uppe…